血小板与淋巴细胞比值在胃癌患者中的临床病理及预后意义

Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer.

作者信息

Gu Xiaobin, Gao Xian-Shu, Cui Ming, Xie Mu, Peng Chuan, Bai Yun, Guo Wei, Han Linjun, Gu Xiaodong, Xiong Wei

机构信息

Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.

Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.

出版信息

Oncotarget. 2016 Aug 2;7(31):49878-49887. doi: 10.18632/oncotarget.10490.

The present study was aim to investigate the prognostic role of platelet to lymphocyte ratio (PLR) for patients with gastric cancer (GC) using meta-analysis. A total of 13 studies (14 cohorts) with 6,280 subjects were included. By pooling hazard ratios (HRs) and 95% confidence intervals (CIs) and odds ratios (ORs) and 95% CIs from each study, we found that elevated PLR was significantly associated with poorer overall survival (OS) (HR: 1.3, 95% CI: 1.1-1.52, p = 0.001; Ι² = 68.5%, Ph < 0.001) but not with poor disease-free survival (DFS) (HR: 1.6, 95% CI: 0.88-2.9, p = 0.122; I2 = 87.8%, Ph < 0.001). Subgroup analysis showed that a high PLR significantly predicted poor OS in Caucasian populations, patients receiving chemotherapy and patients at advanced stage. In addition, the cut-off value of PLR > 160 showed adequately prognostic value. Furthermore, elevated PLR was associated with lymph node metastasis and CEA levels in GC. Our meta-analysis showed that elevated PLR could be a significant prognostic biomarker for poor OS in patients with GC.

本研究旨在通过荟萃分析探讨血小板与淋巴细胞比值（PLR）在胃癌（GC）患者中的预后作用。共纳入13项研究（14个队列），涉及6280名受试者。通过汇总每项研究的风险比（HRs）及95%置信区间（CIs）和比值比（ORs）及95% CIs，我们发现PLR升高与较差的总生存期（OS）显著相关（HR：1.3，95% CI：1.1 - 1.52，p = 0.001；Ι² = 68.5%，Ph < 0.001），但与无病生存期（DFS）较差无关（HR：1.6，95% CI：0.88 - 2.9，p = 0.122；I2 = 87.8%，Ph < 0.001）。亚组分析显示，高PLR显著预示着白种人群、接受化疗的患者及晚期患者的OS较差。此外，PLR > 160的临界值显示出足够的预后价值。此外，PLR升高与GC患者的淋巴结转移及癌胚抗原（CEA）水平相关。我们的荟萃分析表明，PLR升高可能是GC患者OS较差的一个重要预后生物标志物。